Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 215

1.

Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age.

Garland SM, Joura EA, Ault KA, Bosch FX, Brown DR, Castellsagué X, Ferenczy A, Ferris DG, Giuliano AR, Hernandez-Avila M, Huh WK, Iversen OE, Kjaer SK, Kurman RJ, Luna J, Monsonego J, Muñoz N, Paavonen J, Pitisuttihum P, Ronnett BM, Steben M, Stoler MH, Wheeler CM, Wiley DJ, Perez G, Saah AJ, Luxembourg A, Li S, DiNubile MJ, Wagner M, Velicer C.

Obstet Gynecol. 2018 Aug;132(2):261-270. doi: 10.1097/AOG.0000000000002736.

PMID:
29995724
2.

Timely follow-up of positive cancer screening results: A systematic review and recommendations from the PROSPR Consortium.

Doubeni CA, Gabler NB, Wheeler CM, McCarthy AM, Castle PE, Halm EA, Schnall MD, Skinner CS, Tosteson ANA, Weaver DL, Vachani A, Mehta SJ, Rendle KA, Fedewa SA, Corley DA, Armstrong K.

CA Cancer J Clin. 2018 May;68(3):199-216. doi: 10.3322/caac.21452. Epub 2018 Mar 30. Review.

3.

Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S.

Castle PE, Wheeler CM, Campos NG, Sy S, Burger EA, Kim JJ; New Mexico HPV Pap Registry Steering Committee.

Prev Med. 2018 Jun;111:177-179. doi: 10.1016/j.ypmed.2018.03.011. Epub 2018 Mar 14.

PMID:
29548787
4.

Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline.

Arrossi S, Temin S, Garland S, Eckert LO, Bhatla N, Castellsagué X, Alkaff SE, Felder T, Hammouda D, Konno R, Lopes G, Mugisha E, Murillo R, Scarinci IC, Stanley M, Tsu V, Wheeler CM, Adewole IF, de Sanjosé S.

J Glob Oncol. 2017 Mar 17;3(5):611-634. doi: 10.1200/JGO.2016.008151. eCollection 2017 Oct.

5.

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region.

Castellsagué X, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris DG, Joura EA, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, Iversen OE, Kjaer SK, Luna J, Monsonego J, Muñoz N, Myers E, Paavonen J, Pitisuttihum P, Steben M, Wheeler CM, Perez G, Saah A, Luxembourg A, Sings HL, Velicer C.

Papillomavirus Res. 2016 Dec;2:61-69. doi: 10.1016/j.pvr.2016.03.002. Epub 2016 Mar 14.

6.

Going viral? Linking the etiology of human prostate cancer to the PCA3 long noncoding RNA and oncogenic viruses.

Teixeira AA, Marchiò S, Dias-Neto E, Nunes DN, da Silva IT, Chackerian B, Barry M, Lauer RC, Giordano RJ, Sidman RL, Wheeler CM, Cavenee WK, Pasqualini R, Arap W.

EMBO Mol Med. 2017 Oct;9(10):1327-1330. doi: 10.15252/emmm.201708072. No abstract available.

7.

Outcomes in Women With Cytology Showing Atypical Squamous Cells of Undetermined Significance With vs Without Human Papillomavirus Testing.

Cuzick J, Myers O, Lee JH, Shi Y, Gage JC, Hunt WC, Robertson M, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

JAMA Oncol. 2017 Oct 1;3(10):1327-1334. doi: 10.1001/jamaoncol.2017.1040.

8.

An analysis of the process and results of manual geocode correction.

McDonald YJ, Schwind M, Goldberg DW, Lampley A, Wheeler CM.

Geospat Health. 2017 May 11;12(1):526. doi: 10.4081/gh.2017.526.

9.

Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials.

Tota JE, Struyf F, Merikukka M, Gonzalez P, Kreimer AR, Bi D, Castellsagué X, de Carvalho NS, Garland SM, Harper DM, Karkada N, Peters K, Pope WAJ, Porras C, Quint W, Rodriguez AC, Schiffman M, Schussler J, Skinner SR, Teixeira JC, Wheeler CM, Herrero R, Hildesheim A, Lehtinen M; Costa Rica Vaccine Trial and the PATRICIA study groups.

J Natl Cancer Inst. 2017 Jan 28;109(7). doi: 10.1093/jnci/djw300. Print 2017 Jan.

10.

Letter to the Editor in response to O.M. Bautista, A. Luxembourg. Deconstructing the measure of vaccine efficacy against disease irrespective of HPV in HPV vaccine clinical trials. Contemporary Clinical Trials 47 (2016) 254-258.

Folschweiller N, Berlaimont V, Skinner SR, Wheeler CM, Karkada N, Struyf F, Ryser M.

Contemp Clin Trials. 2017 Mar;54:106-107. doi: 10.1016/j.cct.2016.12.022. Epub 2016 Dec 26. No abstract available.

PMID:
28034686
11.

The safety of Cervarix? - Authors' reply.

Wheeler CM, Struyf F; HPV-015 study group.

Lancet Infect Dis. 2017 Jan;17(1):20-21. doi: 10.1016/S1473-3099(16)30540-0. No abstract available.

PMID:
27998562
12.

Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines.

Gage JC, Hunt WC, Schiffman M, Katki HA, Cheung LA, Myers O, Cuzick J, Wentzensen N, Kinney W, Castle PE, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

Obstet Gynecol. 2016 Dec;128(6):1248-1257.

13.

Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era.

Benard VB, Castle PE, Jenison SA, Hunt WC, Kim JJ, Cuzick J, Lee JH, Du R, Robertson M, Norville S, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

JAMA Oncol. 2017 Jun 1;3(6):833-837. doi: 10.1001/jamaoncol.2016.3609.

14.

Population-based prevalence of cervical infection with human papillomavirus genotypes 16 and 18 and other high risk types in Tlaxcala, Mexico.

Rudolph SE, Lorincz A, Wheeler CM, Gravitt P, Lazcano-Ponce E, Torres-Ibarra L, León-Maldonado L, Ramírez P, Rivera B, Hernández R, Franco EL, Cuzick J, Méndez-Hernández P, Salmerón J; FRIDA Study Group.

BMC Infect Dis. 2016 Sep 1;16:461. doi: 10.1186/s12879-016-1782-x.

15.

HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico.

Salmerón J, Torres-Ibarra L, Bosch FX, Cuzick J, Lörincz A, Wheeler CM, Castle PE, Robles C, Lazcano-Ponce E.

Salud Publica Mex. 2016 Apr;58(2):211-9.

16.

Health Service Accessibility and Risk in Cervical Cancer Prevention: Comparing Rural Versus Nonrural Residence in New Mexico.

McDonald YJ, Goldberg DW, Scarinci IC, Castle PE, Cuzick J, Robertson M, Wheeler CM.

J Rural Health. 2017 Sep;33(4):382-392. doi: 10.1111/jrh.12202. Epub 2016 Aug 24.

17.

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.

Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, Garland SM, Chatterjee A, Lazcano-Ponce E, Salmerón J, McNeil S, Stapleton JT, Bouchard C, Martens MG, Money DM, Quek SC, Romanowski B, Vallejos CS, Ter Harmsel B, Prilepskaya V, Fong KL, Kitchener H, Minkina G, Lim YKT, Stoney T, Chakhtoura N, Cruickshank ME, Savicheva A, da Silva DP, Ferguson M, Molijn AC, Quint WGV, Hardt K, Descamps D, Suryakiran PV, Karkada N, Geeraerts B, Dubin G, Struyf F; VIVIANE Study Group.

Lancet Infect Dis. 2016 Oct;16(10):1154-1168. doi: 10.1016/S1473-3099(16)30120-7. Epub 2016 Jun 28.

PMID:
27373900
18.

Corrigendum to "A comparison of cervical histopathology variability using whole slide digitized images versus glass slides: experience with a statewide registry" [HumAN PatholOGY 2013;44:2542-2548].

Gage JC, Joste N, Ronnett BM, Stoler M, Hunt WC, Schiffman M, Wheeler CM.

Hum Pathol. 2016 Jun;52:201. doi: 10.1016/j.humpath.2016.04.001. Epub 2016 May 1. No abstract available.

19.

Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study.

Skinner SR, Wheeler CM, Romanowski B, Castellsagué X, Lazcano-Ponce E, Del Rosario-Raymundo MR, Vallejos C, Minkina G, Pereira Da Silva D, McNeil S, Prilepskaya V, Gogotadze I, Money D, Garland SM, Romanenko V, Harper DM, Levin MJ, Chatterjee A, Geeraerts B, Struyf F, Dubin G, Bozonnat MC, Rosillon D, Baril L; VIVIANE Study Group.

Int J Cancer. 2016 May 15;138(10):2428-38. doi: 10.1002/ijc.29971.

20.

Variation in Screening Abnormality Rates and Follow-Up of Breast, Cervical and Colorectal Cancer Screening within the PROSPR Consortium.

Tosteson AN, Beaber EF, Tiro J, Kim J, McCarthy AM, Quinn VP, Doria-Rose VP, Wheeler CM, Barlow WE, Bronson M, Garcia M, Corley DA, Haas JS, Halm EA, Kamineni A, Rutter CM, Tosteson TD, Trentham-Dietz A, Weaver DL; PROSPR consortium.

J Gen Intern Med. 2016 Apr;31(4):372-9. doi: 10.1007/s11606-015-3552-7.

21.

Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods.

Castro FA, Koshiol J, Quint W, Wheeler CM, Gillison ML, Vaughan LM, Kleter B, van Doorn LJ, Chaturvedi AK, Hildesheim A, Schiffman M, Wang SS, Zuna RE, Walker JL, Dunn ST, Wentzensen N.

BMC Infect Dis. 2015 Nov 25;15:544. doi: 10.1186/s12879-015-1281-5.

22.

Usability Testing of an HPV Information Website for Parents and Adolescents.

Starling R, Nodulman JA, Kong AS, Wheeler CM, Buller DB, Woodall WG.

Online J Commun Media Technol. 2015 Oct;5(4):184-203.

23.

Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.

Gage JC, Hunt WC, Schiffman M, Katki HA, Cheung LC, Cuzick J, Myers O, Castle PE, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):36-42. doi: 10.1158/1055-9965.EPI-15-0669. Epub 2015 Oct 30.

24.

Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.

Kim JJ, Campos NG, Sy S, Burger EA, Cuzick J, Castle PE, Hunt WC, Waxman A, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

Ann Intern Med. 2015 Oct 20;163(8):589-97. doi: 10.7326/M15-0420. Epub 2015 Sep 29.

25.

Fewer than three doses of HPV vaccine - Authors' reply.

Kreimer AR, Struyf F, Hildesheim A, David MP, Wheeler CM; all authors of the manuscript.

Lancet Oncol. 2015 Sep;16(9):e424-e425. doi: 10.1016/S1470-2045(15)00196-5. No abstract available.

PMID:
26370346
26.

HPV16 Down-Regulates the Insulin-Like Growth Factor Binding Protein 2 to Promote Epithelial Invasion in Organotypic Cultures.

Pickard A, McDade SS, McFarland M, McCluggage WG, Wheeler CM, McCance DJ.

PLoS Pathog. 2015 Jun 24;11(6):e1004988. doi: 10.1371/journal.ppat.1004988. eCollection 2015 Jun.

27.

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM; Costa Rica Vaccine Trial Study Group Authors, González P, Jiménez S, Lowy DR, Pinto LA, Porras C, Rodriguez AC, Safaeian M, Schiffman M, Schiller JT, Schussler J, Sherman ME; PATRICIA Study Group Authors, Bosch FX, Castellsague X, Chatterjee A, Chow SN, Descamps D, Diaz-Mitoma F, Dubin G, Germar MJ, Harper DM, Lewis DJ, Limson G, Naud P, Peters K, Poppe WA, Ramjattan B, Romanowski B, Salmeron J, Schwarz TF, Teixeira JC, Tjalma WA; HPV PATRICIA Principal Investigators/Co-Principal Investigator Collaborators; GSK Vaccines Clinical Study Support Group.

Lancet Oncol. 2015 Jul;16(7):775-86. doi: 10.1016/S1470-2045(15)00047-9. Epub 2015 Jun 9.

28.

Prevalent high-risk HPV infection and vaginal microbiota in Nigerian women.

Dareng EO, Ma B, Famooto AO, Adebamowo SN, Offiong RA, Olaniyan O, Dakum PS, Wheeler CM, Fadrosh D, Yang H, Gajer P, Brotman RM, Ravel J, Adebamowo CA.

Epidemiol Infect. 2016 Jan;144(1):123-37. doi: 10.1017/S0950268815000965. Epub 2015 Jun 11.

29.

Investigating stakeholder attitudes and opinions on school-based human papillomavirus vaccination programs.

Nodulman JA, Starling R, Kong AS, Buller DB, Wheeler CM, Woodall WG.

J Sch Health. 2015 May;85(5):289-98. doi: 10.1111/josh.12253.

30.

Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.

Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, Naud P, Salmerón J, Chow SN, Kitchener HC, Teixeira JC, Jaisamrarn U, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Mindel A, de Sutter P, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group.

Clin Vaccine Immunol. 2015 Apr;22(4):361-73. doi: 10.1128/CVI.00591-14. Epub 2015 Feb 4.

31.

The Interpretive Variability of Cervical Biopsies and Its Relationship to HPV Status.

Stoler MH, Ronnett BM, Joste NE, Hunt WC, Cuzick J, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

Am J Surg Pathol. 2015 Jun;39(6):729-36. doi: 10.1097/PAS.0000000000000381.

32.

Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA.

Struyf F, Colau B, Wheeler CM, Naud P, Garland S, Quint W, Chow SN, Salmerón J, Lehtinen M, Del Rosario-Raymundo MR, Paavonen J, Teixeira JC, Germar MJ, Peters K, Skinner SR, Limson G, Castellsagué X, Poppe WA, Ramjattan B, Klein TD, Schwarz TF, Chatterjee A, Tjalma WA, Diaz-Mitoma F, Lewis DJ, Harper DM, Molijn A, van Doorn LJ, David MP, Dubin G; HPV PATRICIA Study Group.

Clin Vaccine Immunol. 2015 Feb;22(2):235-44. doi: 10.1128/CVI.00457-14. Epub 2014 Dec 24.

33.

Human papillomavirus testing 2007-2012: co-testing and triage utilization and impact on subsequent clinical management.

Cuzick J, Myers O, Hunt WC, Saslow D, Castle PE, Kinney W, Waxman A, Robertson M, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

Int J Cancer. 2015 Jun 15;136(12):2854-63. doi: 10.1002/ijc.29337. Epub 2014 Dec 1.

34.

Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer.

Joste NE, Ronnett BM, Hunt WC, Pearse A, Langsfeld E, Leete T, Jaramillo M, Stoler MH, Castle PE, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):230-40. doi: 10.1158/1055-9965.EPI-14-0775. Epub 2014 Nov 2.

35.

Concurrence of multiple human papillomavirus infections in a large US population-based cohort.

Yang Z, Cuzick J, Hunt WC, Wheeler CM.

Am J Epidemiol. 2014 Dec 1;180(11):1066-75. doi: 10.1093/aje/kwu267. Epub 2014 Oct 29.

36.

Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease.

Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, Iversen OE, Kjaer SK, Luna J, Miller D, Monsonego J, Munoz N, Myers E, Paavonen J, Pitisuttithum P, Steben M, Wheeler CM, Perez G, Saah A, Luxembourg A, Sings HL, Velicer C.

Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1997-2008. doi: 10.1158/1055-9965.EPI-14-0410.

37.

Beta-test Results for an HPV Information Web site: GoHealthyGirls.org - Increasing HPV Vaccine Uptake in the United States.

Starling R, Nodulman JA, Kong AS, Wheeler CM, Buller DB, Woodall WG.

J Consum Health Internet. 2014 Jan 1;18(3):226-237.

38.

Human papilloma virions in the laboratory.

Dunne EF, Markowitz LE, Taylor LD, Unger ER, Wheeler CM.

J Clin Virol. 2014 Oct;61(2):196-8. doi: 10.1016/j.jcv.2014.06.014. Epub 2014 Jun 23. Review.

39.

Age-specific prevalence of human papilloma virus infection among Nigerian women.

Akarolo-Anthony SN, Famooto AO, Dareng EO, Olaniyan OB, Offiong R, Wheeler CM, Adebamowo CA.

BMC Public Health. 2014 Jun 27;14:656. doi: 10.1186/1471-2458-14-656.

40.

Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.

Castellsagué X, Naud P, Chow SN, Wheeler CM, Germar MJ, Lehtinen M, Paavonen J, Jaisamrarn U, Garland SM, Salmerón J, Apter D, Kitchener H, Teixeira JC, Skinner SR, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Peters K, Tjalma WA, Safaeian M, Raillard A, Descamps D, Struyf F, Dubin G, Rosillon D, Baril L.

J Infect Dis. 2014 Aug 15;210(4):517-34. doi: 10.1093/infdis/jiu139. Epub 2014 Mar 8.

41.

Three-year risk of cervical precancer and cancer after the detection of low-risk human papillomavirus genotypes targeted by a commercial test.

Castle PE, Hunt WC, Langsfeld E, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

Obstet Gynecol. 2014 Jan;123(1):49-56. doi: 10.1097/AOG.0000000000000013.

42.

Cervical excisional treatment of young women: a population-based study.

Kinney W, Hunt WC, Dinkelspiel H, Robertson M, Cuzick J, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

Gynecol Oncol. 2014 Mar;132(3):628-35. doi: 10.1016/j.ygyno.2013.12.037. Epub 2014 Jan 4.

43.

Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial.

Castellsagué X, Paavonen J, Jaisamrarn U, Wheeler CM, Skinner SR, Lehtinen M, Naud P, Chow SN, Del Rosario-Raymundo MR, Teixeira JC, Palmroth J, de Carvalho NS, Germar MJ, Peters K, Garland SM, Szarewski A, Poppe WA, Romanowski B, Schwarz TF, Tjalma WA, Bosch FX, Bozonnat MC, Struyf F, Dubin G, Rosillon D, Baril L; HPV PATRICIA Study Group.

BMC Infect Dis. 2014 Oct 30;14:551. doi: 10.1186/s12879-014-0551-y.

44.

A population-based evaluation of cervical screening in the United States: 2008-2011.

Cuzick J, Myers O, Hunt WC, Robertson M, Joste NE, Castle PE, Benard VB, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):765-73. doi: 10.1158/1055-9965.EPI-13-0973. Epub 2013 Dec 3.

45.

Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study.

Jaisamrarn U, Castellsagué X, Garland SM, Naud P, Palmroth J, Del Rosario-Raymundo MR, Wheeler CM, Salmerón J, Chow SN, Apter D, Teixeira JC, Skinner SR, Hedrick J, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Germar MJ, Peters K, Paavonen J, Bozonnat MC, Descamps D, Struyf F, Dubin GO, Rosillon D, Baril L; HPV PATRICIA Study Group.

PLoS One. 2013 Nov 19;8(11):e79260. doi: 10.1371/journal.pone.0079260. eCollection 2013. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/cea59317-929c-464a-b3f7-e095248f229a.

46.

The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.

Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Robertson M, Castle PE; New Mexico HPV Pap Registry Steering Committee.

Int J Cancer. 2014 Aug 1;135(3):624-34. doi: 10.1002/ijc.28605. Epub 2014 Apr 15.

47.

HIV associated high-risk HPV infection among Nigerian women.

Akarolo-Anthony SN, Al-Mujtaba M, Famooto AO, Dareng EO, Olaniyan OB, Offiong R, Wheeler CM, Adebamowo CA.

BMC Infect Dis. 2013 Nov 5;13:521. doi: 10.1186/1471-2334-13-521.

48.

No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study.

Wentzensen N, Nason M, Schiffman M, Dodd L, Hunt WC, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

J Infect Dis. 2014 Mar;209(6):855-64. doi: 10.1093/infdis/jit577. Epub 2013 Oct 31.

49.

A comparison of cervical histopathology variability using whole slide digitized images versus glass slides: experience with a statewide registry.

Gage JC, Joste N, Ronnett BM, Stoler M, Hunt WC, Schiffman M, Wheeler CM.

Hum Pathol. 2013 Nov;44(11):2542-8. doi: 10.1016/j.humpath.2013.06.015. Epub 2013 Sep 25.

50.

RPS19 and TYMS SNPs and Prevalent High Risk Human Papilloma Virus Infection in Nigerian Women.

Famooto A, Almujtaba M, Dareng E, Akarolo-Anthony S, Ogbonna C, Offiong R, Olaniyan O, Wheeler CM, Doumatey A, Rotimi CN, Adeyemo A, Adebamowo CA.

PLoS One. 2013 Jun 27;8(6):e66930. doi: 10.1371/journal.pone.0066930. Print 2013.

Supplemental Content

Loading ...
Support Center